• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

BL Research Bureau

Driven by higher revenues of biotechnology products such as insulin and contract research services, Biocon reported 19 per cent growth in net profit in the July-September quarter, on a consolidated basis.

Biopharmaceuticals and branded formulations were major drivers of revenues and the outlook for the same in the coming quarters remains positive.

The company’s strategy to reduce dependence on low-margin statins that are used to reduce cholesterol (30 per cent of its business) seems to be a step in the right direction.

Biocon is expecting its oral insulin programme to do well as it has already announced Phase I human clinical data at the European Association for Study of Diabetes. Oral insulin tablets may turn out to be a major positive for the company although it is yet to announce the positioning strategy for launching the product.

Development of brands in immunosuppressants (treats auto-immune disease) and oncology segments would also aid revenue growth in the coming quarters.

Operating profit margins rose by 4 percentage points to about 29 per cent from a year earlier. Margins received a boost from sale of products like insulin and licensing revenues from the biopharmaceuticals business.

The latter grew by 21 per cent on a year-on-year basis.

Revenues from research services, mainly dollar denominated, from wholly owned subsidiary Syngene sustained strong growth, despite a 3 per cent rise in the rupee during the period.

About 60 per cent of Biocon’s revenue is US dollar-denominated.

Biocon is to invest Rs 275 crore in Syngene over the next two years and expects the unit to contribute significantly in the future.

The focus on the CRAMS business (Contract Research and Manufacturing Services) augurs well for earnings, as margins are much more significant than a pure formulations-driven one.

More Stories on : Stocks | Outlook

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
RCom applies for using mixed technologies

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line